Shares of Insys Therapeutics, Inc. (NASDAQ:INSY) saw an uptick in trading volume on Monday . 1,609,901 shares traded hands during trading, an increase of 201% from the previous session’s volume of 535,509 shares.The stock last traded at $9.95 and had previously closed at $8.88.

Several research analysts have recently commented on the company. BidaskClub raised Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 8th. Royal Bank Of Canada lowered their target price on shares of Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Zacks Investment Research downgraded shares of Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Piper Jaffray Companies set a $10.00 target price on shares of Insys Therapeutics and gave the company a “hold” rating in a research report on Wednesday, July 26th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $14.00 target price on shares of Insys Therapeutics in a research report on Friday, June 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $13.25.

The stock has a 50 day moving average of $9.45 and a 200 day moving average of $11.15. The stock’s market capitalization is $723.34 million.

Insys Therapeutics (NASDAQ:INSY) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The company had revenue of $42.60 million for the quarter, compared to the consensus estimate of $36.90 million. During the same period in the previous year, the business earned $0.13 earnings per share. The firm’s revenue for the quarter was down 38.4% on a year-over-year basis. On average, equities research analysts forecast that Insys Therapeutics, Inc. will post ($0.29) EPS for the current year.

In other Insys Therapeutics news, major shareholder John N. Kapoor Trust Dated Sept acquired 17,500 shares of the company’s stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $8.93 per share, with a total value of $156,275.00. Following the purchase, the insider now directly owns 31,982 shares of the company’s stock, valued at approximately $285,599.26. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Saeed Motahari acquired 5,500 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average cost of $8.92 per share, with a total value of $49,060.00. Following the completion of the purchase, the chief executive officer now directly owns 15,400 shares in the company, valued at $137,368. The disclosure for this purchase can be found here. Insiders own 67.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN raised its position in shares of Insys Therapeutics by 0.5% during the 2nd quarter. Wells Fargo & Company MN now owns 27,667 shares of the specialty pharmaceutical company’s stock valued at $350,000 after buying an additional 126 shares in the last quarter. Eqis Capital Management Inc. lifted its holdings in shares of Insys Therapeutics by 0.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 66,121 shares of the specialty pharmaceutical company’s stock valued at $836,000 after acquiring an additional 404 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Insys Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 79,943 shares of the specialty pharmaceutical company’s stock valued at $1,012,000 after acquiring an additional 475 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Insys Therapeutics by 4.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,576 shares of the specialty pharmaceutical company’s stock valued at $274,000 after acquiring an additional 938 shares during the last quarter. Finally, American International Group Inc. grew its position in Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock worth $152,000 after acquiring an additional 953 shares in the last quarter. Hedge funds and other institutional investors own 25.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insys Therapeutics, Inc. (INSY) Sees Large Volume Increase” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/insys-therapeutics-inc-insy-sees-large-volume-increase/1603919.html.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.